Get the Stockscreener App
3.31
0.60%
-0.02
After Hours:
3.31
Adc Therapeutics Sa stock is traded at $3.31, with a volume of 310.95K.
It is down -0.60% in the last 24 hours and up +12.59% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$3.33
Open:
$3.31
24h Volume:
310.95K
Relative Volume:
0.44
Market Cap:
$372.37M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-1.122
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
-6.50%
1M Performance:
+12.59%
6M Performance:
+78.92%
1Y Performance:
+12.59%
1-Day Range:
$3.27
$3.365
1-Week Range:
$3.20
$3.54
52-Week Range:
$1.05
$3.97
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.31 | 363.37M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Invesco Ltd. Raises Holdings in ADC Therapeutics SA $ADCT - MarketBeat
Owning 30% shares,hedge funds owners seem interested in ADC Therapeutics SA (NYSE:ADCT), - Yahoo Finance
ADC Therapeutics SA (NYSE:ADCT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Nuveen LLC Makes New $214,000 Investment in ADC Therapeutics SA $ADCT - MarketBeat
ADC Therapeutics SA (NYSE:ADCT) Short Interest Update - MarketBeat
Does ADC Therapeutics SA have a sustainable dividendWeekly Gains Summary & Technical Buy Zone Confirmation - Lancaster City Council
Can ADC Therapeutics SA weather a recession2025 Year in Review & Consistent Growth Equity Picks - 뉴스영
Has ADC Therapeutics SA formed a bullish divergenceJuly 2025 Trends & Real-Time Chart Breakout Alerts - Newser
Real time pattern detection on ADC Therapeutics SA stockTrade Analysis Report & Fast Momentum Entry Tips - Newser
Is ADC Therapeutics SA stock influenced by commodity prices2025 Geopolitical Influence & Technical Pattern Recognition Alerts - خودرو بانک
Will breakout in ADC Therapeutics SA lead to full recovery2025 Short Interest & Long-Term Safe Investment Plans - Newser
Nasdaq Moves: What is ADC Therapeutics SA’s book value per share2025 Buyback Activity & Technical Pattern Based Buy Signals - خودرو بانک
ADC Therapeutics SA recovery potential after sell offJobs Report & Momentum Based Trading Signals - Newser
What’s the RSI of ADC Therapeutics SA stock2025 EndofYear Setup & Daily Profit Focused Screening - خودرو بانک
News impact scoring models applied to ADC Therapeutics SAMarket Volume Summary & Consistent Return Investment Signals - Newser
Applying sector rotation models to ADC Therapeutics SA2025 Retail Activity & AI Forecasted Stock Moves - Newser
Using data models to predict ADC Therapeutics SA stock movementQuarterly Performance Summary & High Yield Equity Trading Tips - Newser
Can ADC Therapeutics SA hit a new high this month2025 Volatility Report & Fast Entry and Exit Trade Plans - Newser
Using data tools to time your ADC Therapeutics SA exit2025 Technical Overview & Real-Time Market Sentiment Alerts - Newser
ADC Therapeutics SA stock prediction for this weekMarket Growth Summary & Fast Gain Swing Trade Alerts - Newser
Aug Reactions: Is ADC Therapeutics SA part of any major indexQuarterly Earnings Summary & Consistent Profit Trading Strategies - خودرو بانک
Multi factor analysis applied to ADC Therapeutics SAQuarterly Market Summary & High Return Stock Watch Alerts - Newser
Measuring ADC Therapeutics SA’s beta against major indicesWeekly Gains Report & Smart Money Movement Tracker - Newser
Does ADC Therapeutics SA have consistent dividend growthTrade Volume Summary & High Conviction Investment Ideas - خودرو بانک
What is ADC Therapeutics SA’s book value per shareTreasury Yields & Accurate Intraday Trade Tips - خودرو بانک
Earnings visualization tools for ADC Therapeutics SAMarket Volume Summary & Safe Capital Growth Tips - Newser
What are ADC Therapeutics SA’s earnings expectationsTrade Risk Assessment & Fast Entry Momentum Alerts - خودرو بانک
Can technical indicators confirm ADC Therapeutics SA’s reversalTrade Volume Summary & Free Technical Pattern Based Buy Signals - Newser
What institutional flow reveals about ADC Therapeutics SAWeekly Investment Report & Entry Point Confirmation Signals - Newser
Forecasting ADC Therapeutics SA price range with options dataTake Profit & Fast Entry High Yield Tips - Newser
Is ADC Therapeutics SA stock ready for a breakoutMarket Movement Recap & High Conviction Buy Zone Alerts - Newser
ADC Therapeutics SA stock trend outlook and recovery pathEarnings Overview Summary & Stock Portfolio Risk Management - Newser
Will earnings trigger a reversal in ADC Therapeutics SAQuarterly Performance Summary & Weekly Breakout Stock Alerts - Newser
Published on: 2025-09-03 02:44:03 - Newser
Will ADC Therapeutics SA rebound enough to break evenPortfolio Growth Summary & High Conviction Buy Zone Picks - Newser
Analyzing drawdowns of ADC Therapeutics SA with statistical tools2025 Bull vs Bear & Daily Market Momentum Tracking - Newser
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
Is ADC Therapeutics SA stock poised for growthJuly 2025 Opening Moves & Intraday High Probability Alerts - Newser
Identifying reversal signals in ADC Therapeutics SASwing Trade & Fast Gain Stock Tips - Newser
Is ADC Therapeutics SA part of any major index2025 Technical Patterns & Daily Growth Stock Investment Tips - خودرو بانک
Is ADC Therapeutics SA Forming a Consolidation Base2025 Sector Review & Safe Entry Momentum Tips - beatles.ru
What’s the outlook for ADC Therapeutics SA’s sectorPortfolio Gains Report & Smart Investment Allocation Insights - خودرو بانک
Analyzing ADC Therapeutics SA with risk reward ratio chartsAnalyst Upgrade & Scalable Portfolio Growth Methods - Newser
A | Is ADC Therapeutics SA in a bullish channel2025 Key Highlights & Growth Focused Entry Reports - خودرو بانک
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):